News Categories

• 9/11 Asbestos Risks (4)
• Asbestos & Mesothelioma Studies (95)
• Asbestos Abatement (74)
• Asbestos Bankruptcies (1)
• Asbestos in Products (14)
• Asbestos in Schools (24)
• Asbestos Legislation (58)
• Drug Companies (87)
  • ImClone Systems Incorporated (1)
  • Alfacell (27)
  • Bristol-Myers Squibb (1)
  • CuraGen (1)
  • Eli Lilly (19)
  • Fujirebio Diagnostics, Inc. (9)
  • Genentech (1)
  • Innovive Pharmaceuticals (3)
  • MolMed (1)
  • NeoPharm, Inc. (1)
  • Raptor Pharmaceuticals Corporation (1)
  • Rosetta Genomics (7)
  • Solbec Pharmaceuticals Ltd (1)
  • TopoTarget (1)
  • Zengen, Inc. (1)
• Full Archive (386)
• Libby, MT (15)
• Novel Treatments & Drugs (103)
  • Avastin (3)
  • Carboplatin (Paraplatin®) (8)
  • Cisplatin (Platinol ®) (12)
  • Coramsine (1)
  • Gemcitabine (1)
  • histone deacetylase inhibitors (1)
  • melanocortin receptors (MCR) subtypes MC1R and MC3R (1)
  • MESOMARK (8)
  • Mesothelioma Blood Test (12)
  • Onconase (ranpirnase) (23)
  • Pemetrexed (Alimta) (28)
  • Raltitrexed (Tomudex®) (2)
• Organizations (206)
  • Asbestos Disease Awareness Organization (ADAO) (74)
  • Cancer Monthly (9)
  • Centers for Disease Control (CDC) (4)
  • Environmental Protection Agency (EPA) (67)
  • Environmental Working Group (EWG) (6)
  • Mesothelioma Applied Research Foundation (MARF) (35)
  • NYU Medical Center (1)
• Polio Vaccine – Simian Virus 40 (SV40) (3)
• Trust Funds (10)

Meso News Archives:

• 2012
• 2011
• 2010
• 2009
• 2008
• 2007
• 2006
• 2005
• 2004
• 2003
• 2002
• 2001
• 2000
• 1999
• 1998

You are currently browsing the archives for the melanocortin receptors (MCR) subtypes MC1R and MC3R category.